A Phase I, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SG1-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

The specific purpose of th study is to find out whether SGI-110 given subcutaneously (under the skin) is safe and effective as a treatment for MDS or AML.

Study Number: 

PH 197411

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.